CA-AGENDIA,-INC.
18.11.2020 13:02:29 CET | Business Wire | Press release
Agendia, Inc ., a world leader in precision oncology for breast cancer, and Paige , a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai , https://www.paigeplatform.com , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 14:01:00 CEST | Press release
Prelude Ventures led the round, with participation from JERA Co., Inc., Japan's largest power generation company, and Idemitsu Kosan, one of Japan's largest integrated energy companies Series B equity is the first component of a diverse financing that includes project-level capital and debt Quaise's millimeter wave drilling system is approaching one kilometer of depth at its Central Texas field site Series B proceeds fund Project Obsidian in Central Oregon, the world’s first commercial superhot geothermal power plant Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features mult
UMA Unveils Its Vision for the Next Generation of Humanoid Robots7.7.2026 14:00:00 CEST | Press release
At Machina Summit, UMA unveils the design of its first humanoid robot and introduces Real-Time Learning, a new AI architecture that enables robots to learn new skills through demonstration rather than programming. At Machina Summit, UMA, a Physical AI company, unveiled the design of its first humanoid robot and introduced Real-Time Learning, a learning architecture that enables robots to acquire new skills through demonstration instead of manual programming. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707215927/en/ The announcement comes as aging populations, industrial reshoring, and the energy transition place increasing pressure on labor markets across advanced economies. According to Korn Ferry, the global economy could face a shortage of 85 million workers by 2030, representing as much as $8.5 trillion in unrealized economic output. Against this backdrop, UMA is developing a new generation of intelligent robots bu
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 14:00:00 CEST | Press release
Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W
Bregal Milestone III Closes at its Increased Hard Cap of €915 Million7.7.2026 13:00:00 CEST | Press release
Oversubscribed fundraise with global institutional backing Bregal Milestone (“Milestone” or the “Firm”), a leading European software private equity firm, today announced the final close of its third fund, Bregal Milestone III (“Fund III” or the “Fund”), at its increased hard cap of €915 million. The Fund was oversubscribed and marks a significant broadening of the Firm’s global investor base. Completed in eight months from first close and achieved against a challenging fundraising environment, the result reflects the strength of Milestone’s AI-centric approach and demonstrable track record. Jan Bruennler, Philippe Lautenberg and Cyrus Shey, Co-Founders and Managing Partners at Bregal Milestone, commented: “Bregal Milestone III reflects strong conviction in our approach to investing in mission-critical European software, AI and cybersecurity businesses and helping them scale. We are thankful for the support and confidence shown by our limited partners, both longstanding and new, and rem
HTEC and Embotech Partner to Scale Deployment of Autonomous Driving Solutions for Industrial Logistics7.7.2026 12:39:00 CEST | Press release
HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707870943/en/ HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. The partnership comes as Embotech’s proven autonomous driving solutions are being adopted across a growing number of vehicle platforms
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom